Results from two Phase I studies demonstrate that immune checkpoint inhibitors may be beneficial for patients with certain cancers of the esophagus and stomach. Roughly one-third of patients in the studies had their disease controlled by nivolumab or pembrolizumab, according to presentations at the 2016 Gastrointestinal Cancers Symposium (abstracts 6 and 7).
http://www.clinicaloncology.com/Other-Solid-Tumors/Article/03-16/Immunotherapy-Trials-Show-Promise-Against-Stomach-Esophagus-Ca/35568
Immunotherapy Trials Show Promise Against Stomach and Esophagus Cancers